EMA delays Valneva vaccine approval
The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agencys CHMP requested additional data.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Mimetas BV participating in €325m cancer funding
Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharmas imlifidase advances to Phase III testing
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
A 3D tumour model developed by scientists enables drug screening in metastases
Vetter wins at the 2022 CMO Leadership Awards
Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
Affimed prices public offering to finance NK cell trials
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Lead optimisation – the sequence is the key
The efficacy of therapeutic antibodies is defined by their primary amino acid sequence. After discovery, antibody candidates often profit from protein engineering and sequence optimisation. Different technologies can improve the functional properties of antibodies as well as their biochemical and biophysical characteristics influencing manufacturing, process development, formulation, and other parameters of the final drug target product profile.
A new purification workflow
Biologicals have shown significant success for more complex diseases, whereas small molecule drugs have not been that effective. New biologicals are mostly highly purified proteins or antibodies, which require the development of technologies for the preparation of a large number of drug candidates with high purity and speed. A high throughput magnetic beads-based system is a game-changer for biologics discovery.